EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients

Camille Kockerols, Peter J M Valk, Jeroen J W M Janssen, Pauline Hogenbirk, Jan J Cornelissen, Susanne Saussele, Birgit Spiess, Maria Agustina Perusini, Dennis Kim iD, Peter E Westerweel iD

European Journal of Haematology · 2024-11 · 113 (5) · 606-613

DOI: 10.1111/ejh.14271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 12.07.2024. Verfasst von Camille Kockerols und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Polymerase Chain Reaction, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of molecular response measured by BCR::ABL1 digital PCR (dPCR). The aim of this study was to validate a previously described prediction cutoff of 0.0023% IS and to assess the value of dPCR for treatment‐free remission (TFR) prediction in relation to other clinical parameters. A droplet‐based dPCR assay assessed BCR::ABL1 % IS prior to TKI discontinuation. The primary endpoint was molecular recurrence (MolR) by 36 months. A total of 186 patients from Canada, Germany, and the Netherlands were included. In patients with a first TKI discontinuation attempt ( n = 163), a BCR::ABL1 dPCR < and ≥0.0023% IS had a MolR probability of 33% and 70%, respectively. Patients treated less than 6 years with a BCR::ABL1 dPCR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositivePolymerase Chain ReactionProtein Kinase InhibitorsHumansPrognosisProto-Oncogene Proteins c-ablRemission InductionTreatment OutcomeTyrosine Kinase InhibitorsCanadaGermanyNetherlands

Stichwörter der Autor:innen

BCR::ABL1 digital PCRchronic myeloid leukemiatreatment‐free remissiontyrosine kinase inhibitor discontinuation

Substanzen

Fusion Proteins, bcr-ablProtein Kinase InhibitorsProto-Oncogene Proteins c-ablTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • III. Med Clinic, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

ORCID-Profile: Dennis Kim, Peter E Westerweel

Zitieren

APA

Kockerols, C., Valk, P. J. M., Janssen, J. J. W. M., Hogenbirk, P., Cornelissen, J. J., Saussele, S., Spiess, B., Perusini, M. A., Kim, D., & Westerweel, P. E. (2024). Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients. European Journal of Haematology, 113(5), 606-613. https://doi.org/10.1111/ejh.14271

Vancouver

Kockerols C, Valk PJM, Janssen JJWM, Hogenbirk P, Cornelissen JJ, Saussele S, et al. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients. European Journal of Haematology. 2024;113(5):606-613. doi:10.1111/ejh.14271

BibTeX
@article{Kockerols2024,
  author = {Kockerols, Camille and Valk, Peter J M and Janssen, Jeroen J W M and Hogenbirk, Pauline and Cornelissen, Jan J and Saussele, Susanne and Spiess, Birgit and Perusini, Maria Agustina and Kim, Dennis and Westerweel, Peter E},
  title = {Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR :: ABL1 digital PCR in chronic myeloid leukemia patients},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {113},
  number = {5},
  pages = {606--613},
  doi = {10.1111/ejh.14271}
}
Kostenlos starten →